CONSOLIDATED FINANCIAL REPORT
For the First Quarter of Fiscal 2010
(the Fiscal Year Ending March 31, 2011, Japan Standard)

July 30, 2010

Eisai Co., Ltd.
Stock exchange listings: Tokyo Osaka
TSE Code: 4523
URL http://www.eisai.co.jp
Representative: Haruo Naito, Director, President & CEO

2. Dividends

	Dividend per share				
	1Q end	2Q end	3Q end	Year-end	Total
Fiscal 2009	(¥)	(¥) 70.00	(¥)	(¥) 80.00	(¥) 150.00
Fiscal 2010					
Fiscal 2010 (Forecast)		70.00		80.00	150.00

Performance by Segment

(Net sales for each segment include only sales to external customers.)

Details concerning performance by segment are provided in accordance with the "Revised Accounting Standard for Disclosures about Segments of an Enterprise and Related Information" (Accounting Standards Board of Japan (ASBJ) Statement No. 17 released on March 27, 2009) and the "Guidance on Accounting Standard for Disclosures about Segments of an Enterprise and Related Information" (ASBJ Guidance No. 20 released on March 21, 2008), which were adopted effective from the first quarter of the fiscal year ending March 31, 2011. In addition, indices that compare data with the same period of the previous fiscal year are provided for reference purposes only. For segment information details, please refer to pages 15.

Japan Pharmaceuticals Business

- **Net sales** totaled ¥86,172 million (up 5.6% year on year), with **segment profit** of ¥36,809 million (up 7.1% year on year).
- **Sales of Aricept** increased to ¥25,271 million (up 8.0% year on year), and **sales of Pariet** increased to ¥15,093 million (up 12.6% year on year).

United States Pharmaceuticals Business

- **Net sales** totaled ¥88,554 million (up 6.7% year on year; up 12.9% on a U.S. dollar-denominated basis) with **segment profit** of ¥26,512 million (up 19.8% year on year).
- **Sales of Aricept** came to ¥50,170 million (up 17.6% year on year; up 24.4% on a U.S. dollar-denominated basis), and **sales of Aciphex** came to ¥16,980 million (down 14.2% year on year; down 9.2% on a U.S. dollar-denominated basis).

Europe Pharmaceuticals Business

- **Net sales** totaled ¥11,119 million (down 10.0% year on year), with **segment profit** of ¥1,278 million (down 36.1% year on year).
- **Sales of Aricept** came to ¥5,775 million (down 19.3% year on year), and **sales of Pariet** came to ¥1,815 million (down 11.9% year on year).

Asia Pharmaceuticals Business

- **Net sales** totaled ¥8,758 million (up 17.4% year on year), with **segment profit** of ¥2,090 million (up 0.2% year on year).
- **Sales of Aricept** came to ¥1,676 million (up 7.6% year on year), and **sales of Pariet** came to ¥1,323 million (down 5.6% year on year).

New Markets Pharmaceuticals Business

- **Net sales** totaled ¥264 million (up 30.3% year on year), with **segment loss** of ¥62 million.
- **Sales of Aricept** (brand name in India: Aricep) came to ¥34 million (up 21.0% year on year), and **sales of Pariet** (brand name in India: Parit) came to ¥72 million (up 46.0% year on year).

(2) Research & Development Projects, Alliances, and Other Events

Status of Ongoing Research & Development Projects

,

Status of Major Alliances and Agreements

- In June 2010, Eisai's U.S. subsidiary **Eisai Inc. concluded an exclusive license agreement with Helsinn Healthcare S.A. of Switzerland** for the commercialization of a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the U.S. The arrangement covers the development of a combination antiemetic agent (in both oral and intravenous forms) containing netupitant (generic name), a neurokinin-1 receptor antagonist, and palonosetron (generic name, brand

(3) Qualitative Information Concerning Financial Position

Assets, Liabilities and Equity

- **Total assets** as of the end of this period amounted to ¥1,065,528 million (down ¥36,381 million from the end of the previous fiscal year). Major decreases included decreases in intangible assets due to the foreign currency loss in the yen conversion.
- **Total liabilities** as of the end of this period amounted to ¥667,396 million (down ¥12,773 million from the end of the previous fiscal year).
-

(5) Corporate Governance

1) Appointment of Directors

Eleven Directors, including seven Outside Directors, were appointed and assumed their respective offices effective June 18, 2010, the date of the 98th Ordinary General Meeting of Shareholders.

Candidates for Director were selected by the Nomination Committee in accordance with the Committee's selection criteria, and the list was presented for approval at the General Meeting of Shareholders. Outside Directors in particular must meet the requirements for Outside Directors set forth in Article 2-3-7 of the Ordinance for Enforcement of Japan's Companies Act, as well as satisfy the following Independence and Neutrality Requirements established by the Nomination Committee.

Requirements for the Independence and Neutrality of Outside Directors

(Revised on January 30, 2009)

1. An Outside Director must be economically independent from Eisai Co., Ltd. or its affiliated companies (hereinafter referred to as the Eisai Group collectively) as well as from specified enterprises, etc., as demonstrated by satisfying the following conditions:
   - i) An Outside Director must not have received directly from the Eisai Group, in the past five years, compensation or remuneration for work or transactions (excluding director compensation from Eisai) at or above the fixed amount defined as follows:
     - a The "fixed amount" is defined as ¥10 million or more in any given fiscal year out of the past five years.
     - b Even when the individual has received the amount indirectly, the actual situation shall be judged prudently.
   - ii) An Outside Director must not have been, in the past five years, a Director, Executive Officer, or other officer of the any of the types of enterprises (including holding companies) defined as follows:
     - a Enterprises, etc., for which 2% or more of its sales in any given fiscal year out of the past five years have been sales or compensation for work or transactions with the Eisai Group;
     - b Regardless of the previous item, enterprises, etc., with a relationship of substantial interest with Eisai or its affiliated companies, such as Eisai's audit corporation;
     - c Enterprises, etc., that are major shareholders of the company (holding 10% or more of the company's outstanding shares); or
     - d Enterprises, etc., in which the Eisai Group is a major shareholder (holding 10% or more of the outstanding shares of the relevant enterprise, etc.)
   - iii) Even if an Outside Director has retired from their position as a Director, Executive Officer, or other officer of the types of enterprises specified above, the Nomination Committee must determine that the Outside Director is independent and neutral with respect to these enterprises based on consideration of the following factors:
     - a The Outside Director's shareholding in the relevant enterprise, etc.
     - b The Outside Director's post-retirement remuneration from the relevant enterprise, etc.
     - c Human interaction between the Eisai Group and the relevant enterprise, etc.
2. An Outside Director must not be a close relative of, or one having a similar relationship to, a Director or Executive Officer of the Eisai Group.
   - i) A "close relative" is defined as a spouse, a blood relative within three degrees of kinship, or a cohabitating relative.
   - ii) "One having a similar relationship to" is defined as one having a human relationship that can be rationally recognized as that which makes it impossible for the individual to fulfill duties as an independent Director, such as a personally interested individual.
3. An Outside Director may not be of the same household as persons with any of the conflicts of interest described in paragraph 1.
4. In addition, there must not be any other situations rationally recognizable as preventing an Outside Director from performing duties as an independent Director.
5. The requirements for the independence and neutrality of Outside Directors defined in this article continue to apply after the appointment as Outside Director.

2) Structure of the Board of Directors and Executive Officers

At the Board of Directors meeting held following the closing of the 98th Ordinary General Meeting of Shareholders, the Chair of the Board of Directors, as well as Chairs and members of the Nomination, Audit and Compensation committees, were appointed and assumed office.

Director	Haruo Naito	President (Representative Executive Officer) and CEO
Director	Hiroyuki Mitsui	
Director	Akira Fujiyoshi	Audit Committee Member
Director	Norio Kano	Audit Committee Member
Outside Director	Norihiko Tanikawa	Chairman of the Board
Outside Director	Satoru Anzaki	Chair of the Nomination Committee, Compensation Committee Member
Outside Director	Junji Miyahara	Nomination Committee Member, Compensation Committee Member
Outside Director	Kimitoshi Yabuki	Audit Committee Member
Outside Director	Christina Ahmadjian	Audit Committee Member
Outside Director	Tokuji Izumi	Chair of the Compensation Committee, Nomination Committee Member
Outside Director	Koichi Masuda	Chair of the Audit Committee

The Independent Committee of Outside Directors (Chair: Kimitoshi Yabuki), at a meeting on June 18, 2010, determined that the “Policy for Protection of the Company’s Corporate Value and Common Interests of Shareholders” (the “Policy”) incorporates the following provisions, and that except for the deletion of phrases pertaining to the real register of shareholders as a result of the digitization of stock certificates, recommended to the Board of Directors that it be continued in its present form.

a) The Policy precludes arbitrary action on the part of management.
b) The continuation, amendment or abandonment of the Policy shall be deliberated every year.
c) Shareholders’ opinions concerning the Policy may be reflected through the election of Directors at the Ordinary General Meeting of Shareholders.

At the Board of Directors meeting held on July 30, 2010, a proposal by the Independent Committee of Outside Directors regarding continuing application of the Policy was approved and resolved, and the company announced it as the “Policy for Protection of the Company’s Corporate Value and the Common Interests of Shareholders” in a press release issued on the same day.

For further details on the Policy, please visit the web site:
http://www.eisai.co.jp/ecompany/egovernance.html

2. Other Information

(1) Application of the Simplified Accounting Method and Special Accounting Treatment

1) Simplified accounting method

The calculation of the value of inventories as of the end of the quarter ended June 30, 2010 has been made in a rational manner based on the actual inventory value as of the end of the previous fiscal year.

2) Special accounting treatment used in the preparation of consolidated quarterly financial statements: None

(2) Summary of Changes of Accounting Principles, Procedures and Representation Methods in Connection with the Preparation of Consolidated Financial Statements

1) The accounting standard and guidance concerning asset retirement obligations, the "Accounting Standard for Asset Retirement Obligations" (ASBJ Statement No.cET/T02 0 Td[dd /n001p

3. Consolidated Financial Statements

(1) Consolidated Banalnce Sheets

(millions of yen)

ASSETS		
Current assets:		
Cash and cash in banks	69,380	69,637
Notes and accounts receivable-trade	213,533	207,219
Short-term investments	75,384	83,823
Merchandise and finished goods	37,007	36,564
Work in process	16,376	19,676
Raw materials and supplies	12,727	11,313
Deferred tax assets	39,470	32,457
Other	19,420	19,591
Allowance for doubtful receivables	(258)	(239)
Total current assets	483,042	480,044
Non-current assets:		
Property, plant and equipment		
Buildings and structures-net	84,388	86,525
Other-net	68,017	70,117
Total property, plant and equipment	152,406	156,642
Intangible assets		
Goodwill	143,119	152,768

(millions of yen)

LIABILITIES		
Current liabilities:		
Notes and accounts payable-trade	23,029	20,314
Short-term borrowings	16,000	24,000
Bonds and debentures(Current portion)	39,998	-
Accounts payable-other	59,469	67,913
Accrued expenses	58,344	59,657
Income tax payable	12,899	6,555
Reserve for sales rebates	33,243	32,723
Other reserves	492	556
Other	7,756	8,523

(2) Consolidated Statements of Income

(millions of yen)

	April 1, 2009- June 30, 2009	April 1, 2010- June 30, 2010
Net sales	194,671	204,463
Cost of sales	38,289	43,577
Gross profit	156,381	160,885
Provision for sales returns-net	52	
Reversal of reserve for sales returns-net		35
Gross profit after deducting provision for sales returns-net	156,328	160,921
Selling, general and administrative expenses	*1 132,184	*1 128,148
Operating income	24,144	32,773
Non-operating income		
Interest income	320	215
Dividend income	469	519
Foreign exchange gain	541	-
Other	65	90
Total non-operating income	1,397	825
Non-operating expenses		
Interest expenses	2,060	1,885
Foreign exchange loss	-	1,453
Other	303	92
Total non-operating expenses	2,364	3,431
Ordinary income	23,177	30,167
Special gain		
Gain on sales of fixed assets	2	27
Other	2	19
Total special gain	5	46
Special loss		
Loss on disposal of fixed assets	36	48
Loss on devaluation of investment securities	-	321
Effect of application of an accounting standard of asset retirement obligations	-	654
Other	0	2
Total special loss	37	1,028
Income before income taxes and minority interests	23,145	29,185
Income taxes-current	13,291	12,490
Income taxes-deferred	(6,674)	(2,203)
Total income taxes	6,617	10,287
Income before minority interests	-	18,898
Minority interests in income	178	109
Net income	16,349	18,789

(3) Consolidated Statements of Cash Flows

(4) Going Concern

Not applicable

(5) Segment Information

1) Summary of reporting segments

The Group defines its reporting segments as follows: units that comprise the Group of which it can obtain independent financial information; units of which Top management undertakes a periodic review in order to determine the allocation of management resources and to evaluate performance.

The Group's Pharmaceuticals business is classified into five segments comprising Japan, the United States, Europe, Asia (including China) and New Markets (India, Middle East, etc). Steps are taken to pursue strategies and plans that take into account the specific characteristics and attributes of each region or market. In the Pharmaceuticals business, the Group is mainly engaged in the manufacture and sale of prescription drugs.

The Group's business consists of the Pharmaceuticals and Other businesses and the Pharmaceuticals business of each region is identified as a reporting segment.

2) Information concerning sales, profit (and loss) by reporting segment

First Quarter of Fiscal 2010 (April 1, 2010 to June 30, 2010)

(Millions of yen)

	Reporting Segment						Other (Note)	Total
	Japan Pharma-ceuticals Business	US Pharma-ceuticals Business	Europe Pharma-ceuticals Business	Asia Pharma-ceuticals Business	New Markets Pharma-ceuticals Business	Subtotal		
Sales to external customers	86,172	88,554	11,119	8,758	264	194,868	9,595	204,463
Segment profit (loss)	36,809	26,512	1,278	2,090	(62)	66,628	4,076	70,704

Note: "Other" is a business segment not included in reporting segments. Pharmarceutical raw materials and machinery businesses are included in this segment.

3) The amount and major details of differences between reporting segment profit and loss totals and amounts reported in the quarterly consolidated statements of income (items concerning difference adjustment)

(Millions of yen)

Profit	Amount
Reporting segment profit total	66,628
Profit of Other	4,076
R&D expenses	(36,028)
Non-allocated SG&A expenses	(1,903)
Operating income as recorded in quarterly consolidated financial statements	32,590

Forward-looking Statements and Risk Factors

Materials and information provided in this financial disclosure may contain “forward-looking statements” based on current expectations, forecasts, estimates, business goals and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions, such as interest rate and currency exchange fluctuations.

Risks that may cause significant fluctuations in the consolidated results of the Company or have a material effect on decisions of shareholders are described below. These are risk factors that have been identified and assessed as of the disclosure date of the Financial Report. Risk factors associated with our business include, but are not limited to, challenges arising out of global expansion, uncertainties in new drug development, risks related to strategic alliances with partners, healthcare cost-containment measures, intensified competition with generic drugs, intellectual property, possible incidence of adverse events, compliance with laws and regulations, litigation, closure or shutdown of factories, safety issues of raw materials used, outsourcing-related risks, environmental issues, IT security/information management, and conditions of financial markets, foreign exchange fluctuations, and internal control systems.

Contents

1. **Consolidated Financial Highlights** ---------- **1**
2. **Consolidated Statements of Income** ---------- **3**
3. **Consolidated Statements of Cash Flows** ---------- **4**
4. **Financial Results by Business Segment** ---------- **5**
5. **Consolidated Balance Sheets** ---------- **10**
6. **Changes in Consolidated Quarterly Results** ---------- **12**
7. **Non-Consolidated Financial Highlights** ---------- **16**
8. **Major Events** ---------- **18**
9. **Major R&D Pipeline** ---------- **19**

* All amounts are rounded to their nearest specified unit.
* The exchange rates used in the reference data are noted in the table below.
* All amounts of overseas profit and loss are converted into yen based on the average exchange rates for the periods shown in the table below.

Currency Exchange Rates

	US (¥/USD)	EU (¥/EUR)	UK (¥/GBP)	China (¥/RMB)
(Apr. 2009 - Jun. 2009) Three Months Average Rate	97.32	132.57	150.77	14.25
(Jun. 30, 2009) First Quarter End Rate	96.01	135.53	159.54	14.05
(Apr. 2009 - Mar. 2010) Fiscal Year Average Rate	92.84	131.15	148.25	13.57
(Mar. 31, 2010) Fiscal Year End Rate	93.04	124.92	140.40	13.63
(Apr. 2010 - Jun. 2010) Three Months Average Rate	92.00	116.99	136.98	13.48
(Jun. 30, 2010) First Quarter End Rate	88.48	107.81	133.07	13.03
Fiscal Year Ending March 31, 2011 Forecast Rate	90.00	125.00	145.00	13.00

About Indications in this Reference Data

Eisai believes that cash generating ability is the most intrinsic element determining the true value of a company. Upon this basic concept, in order to reflect our true earnings capacity, we focus on disclosing “cash income” and “cash EPS,” which are not affected by non-cash profit-and-loss items, such as depreciation of property, plant and equipment, amortization of goodwill, loss on impairment (including loss on devaluation of investment securities), and in-process R&D expenses.

Cash income

Cash income is the total amount of cash available for investment in future growth and business development, dividend payments, repayment of borrowings, and other expenditures. We consider cash income as an indicator to assess corporate growth potential and strategies.

Cash income = Net income + Depreciation of PP&E and amortization of intangible assets + In-process R&D expenses + Amortization of goodwill + Loss on impairment of long-lived assets (including loss on devaluation of investment securities)

Cash income per share (Cash EPS)

Cash EPS = Cash income / Number of shares issued and outstanding at the end of the year after deducting treasury stocks

Segment information

Details concerning performance by segment are provided in accordance with the “Revised Accounting Standard for Disclosures about Segments of an Enterprise and Related Information” (Accounting Standards Board of Japan (ASBJ) Statement No. 17 released on March 27, 2009) and the “Guidance on Accounting Standard for Disclosures about Segments of an Enterprise and Related Information” (ASBJ Guidance No. 20 released on March 21, 2008), which were adopted effective from the first quarter of the fiscal year ending March 31, 2011. In addition, indices that compare data with the same period of the previous fiscal year are provided for reference purposes only.

1. Consolidated Financial Highlights

1) Income Statement Data

(billions of yen)

	Three months ended Jun 30			Full	
	FY2009	FY2010	YOY %	FY2009	FY2010 est.
Net sales	194.7	204.5	105.0	803.2	810.0
Cost of sales	38.3	43.5	113.6	160.7	169.0
R&D expenses	39.4	36.0	91.5	179.1	157.0
SG&A expenses	92.8	92.1	99.3	376.9	379.0
Operating income	24.1	32.8	135.7	86.4	105.0
Ordinary income	23.2	30.2	130.2	79.7	98.5
Net income	16.3	18.8	114.9	40.3	65.0
Cash income	30.7	32.6	106.2	126.4	120.0
			Diff.		
Dividend per share (DPS, yen)	-	-	-	150.0	150.0
Earnings per share (EPS, yen)	57.4	65.9	8.6	141.6	228.1
Cash income per share (Cash EPS, yen)	107.7	114.4	6.6	443.7	421.2

* "Cost of sales" includes "Provision for (reversal of) sales returns-net."

2) Cash Flow Data

(billions of yen)

	Three months ended Jun 30			Full
	FY2009	FY2010	Diff.	FY2009
Net cash provided by (used in) operating activities	(0.5)	28.2	28.7	107.9
Net cash used in investing activities	(12.9)	(5.1)	7.8	(69.8)
Net cash provided by (used in) financing activities	(12.3)	(31.1)	(18.9)	(49.2)
Cash and cash equivalents at end of period	105.2	101.4	(3.8)	115.1
Free cash flow	(10.7)	23.9	34.6	52.9

* "Free cash flow" = "Net cash provided by (used in) operating activities" - "Capital expenditures (incl. acquisition and others)"

3) Balance Sheet Data

(billions of yen)

		2010	
	Mar 31	Jun 30	Diff.
Total assets	1101.9	1,065.5	(36.4)
Liabilities	680.2	667.4	(12.8)
Bonds and debentures	120.0	120.0	0.0
Borrowings	289.8	279.1	(10.7)
Equity	421.7	398.1	(23.6)
Shareholders' equity	415.9	392.3	(23.6)
Shareholders' equity ratio to total assets (%)	37.7	36.8	(0.9)
Liabilities ratio Net DER/times)	0.6	0.6	0.0

* "Liabilities ratio Net DER)" = ("Interest-bearing debt" ("Borrowings" + "Bonds and debentures") - "Cash and cash in banks" - "Short-term investments" / "Shareholders' equity"

4) Capital Expenditures and Depreciation/Amortization

(billions of yen)

	Three months ended Jun 30			Full
	FY2009	FY2010	Diff.	FY2009
Capital expenditures	5.8	3.5	(2.3)	28.7
Property, plant and equipment	4.8	2.5	(2.3)	22.9
Intangible assets	1.0	1.0	0.0	5.8
Depreciation and amortization	12.1	11.4	(0.7)	48.9

* "Depreciation and amortization" includes amortization of "Intangible assets."

5) Financial Results by Business Segment

(1) Consolidated Net Sales by Reporting Segment

(billions of yen)

	Three months ended Jun 30		
	FY2009	FY2010	YOY %
Japan pharmaceuticals business	81.6	86.2	105.6
US pharmaceuticals business	83.0	88.6	106.7
Europe pharmaceuticals business	12.4	11.1	90.0
Asia pharmaceuticals business	7.5	8.8	117.4
New markets pharmaceuticals business	0.2	0.3	130.3
Other	10.1	9.6	95.1
Consolidated net sales	194.7	204.5	105.0

* Net sales to external customers for each segment.

(2) Consolidated Operating Income by Reporting Segment

(billions of yen)

	Three months ended Jun 30		
	FY2009	FY2010	YOY %
Japan pharmaceuticals business	34.4	36.8	107.1
US pharmaceuticals business	22.1	26.5	119.8
Europe pharmaceuticals business	2.0	1.3	63.9
Asia pharmaceuticals business	2.1	2.1	100.2
New markets pharmaceuticals business	(0.0)	(0.1)	-
Other profit	4.7	4.1	86.1
R&D expenses	39.4	36.0	91.5
Non-allocated SG&A expenses	1.8	1.9	108.1
Operating income	24.1	32.8	135.7

*The Group's Pharmaceuticals business is classified into five segments comprising Japan, the United States, Europe, Asia and New Markets (India, Middle East, etc). Steps are taken to pursue strategies and plans that take into account the specific characteristicsand attributes of each region or market. In the Pharmaceuticals business, the Group is mainly engaged in the manufacture and sale of prescription drugs.

2. Consolidated Statements of Income

(billions of yen)

	Three months ended Jun 30						Full	
	FY2009	Sales %	FY2010	Sales %	YOY %	Diff.	FY2009	Sales %
Net sales	194.7	100.0	204.5	100.0	105.0	9.8	803.2	100.0
Cost of sales	38.3	19.7	43.5	21.3	113.6	5.2	160.7	20.0
Gross profit	156.3	80.3	160.9	78.7	102.9	4.6	642.4	80.0
R&D expenses	39.4	20.2	36.0	17.6	91.5	(3.4)	179.1	22.3
SG&A expenses	92.8	47.7	92.1	45.1	99.3	(0.7)	376.9	46.9
Personnel expenses	21.3	10.9	20.5	10.0	96.6	(0.7)	83.4	10.4
Marketing and promotion expenses	56.3	28.9	57.3	28.0	101.8	1.0	234.0	29.1
Administrative expenses and others	15.2	7.8	14.3	7.0	93.6	(1.0)	59.5	7.4
Operating income	24.1	12.4	32.8	16.0	135.7	8.6	86.4	10.8
Non-operating income	1.4	0.7	0.8	0.4		(0.6)	2.4	0.3
Non-operating expense	2.4	1.2	3.4	1.7		1.1	9.1	1.1
Ordinary income	23.2	11.9	30.2	14.8	130.2	7.0	79.7	9.9
Special gain	0.0	0.0	0.0	0.0		0.0	0.1	0.0
Special loss	0.0	0.0	1.0	0.5		1.0	5.5	0.7
Income before income taxes and minority interests	23.1	11.9	29.2	14.3	126.1	6.0	74.3	9.2
Income taxes-current	13.3	6.8	12.5	6.1		(0.8)	26.8	3.3
Income taxes-deferred	(6.7)	(3.4)	(2.2)	(1.1)		4.5	6.6	0.8
Minority interests in net income	0.2	0.1	0.1	0.1		(0.1)	0.5	0.1
Net income	16.3	8.4	18.8	9.2	114.9	2.4	40.3	5.0

* "Cost of Sales" includes "Provision for (reversal of) sales returns-net."

Cash income

Net income	16.3	8.4	18.8	9.2	114.9	2.4	40.3	5.0
Depreciation of PP&E and amortization of intangible assets	7.1		6.7				29.8	
Amortization of intangible assets obtained by acquisition	5.0		4.7				19.1	
In-process R&D expenses	-		-				23.9	
Amortization of goodwill	2.2		2.1				8.5	
Loss on impairment of long-lived assets (including loss on devaluation of investment securities)	-		0.3				4.9	
Cash income	30.7	15.8	32.6	15.9	106.2	1.9	126.4	15.7

Notes

Net sales	<Reason for Increase> Increase in sales of Aricept [+8.1billions of yen], Increase in sales of Humira [+1.8 billion yen], Decrease in sales of Aciphex [-1.4 billion yen]
Ratio of cost of sales	<Reason for Increase> Drug price revision in Japan, influences of currency exchange, change of product mix etc.
R&D expenses	<Reason for decrease> Influence of currency exchange and others
SG&A expenses	<Reason for decrease> Improve the efficiency in administration cost and others
Non-operating expense	<Reason for decrease> Decrease in foreign exchange loss [-1.5billions of yen]
Special loss	<Reason for Increase> Effect of applying accounting standard for asset retirement obligations [-0.7billions of yen]

3. Consolidated Statements of Cash Flows

(billions of yen)

	Three months ended Jun 30		
	FY2009	FY2010	Diff.
Income before income taxes and minority interests	23.1	29.2	6.0
Depreciation and amortization	12.1	11.4	(0.7)
Decrease (increase) in notes and accounts receivable, trade payables and inventories	(7.4)	(8.0)	(0.6)
Increase (decrease) in accounts payable-other/accrued expenses etc.	(1.1)	(2.4)	(1.2)
Other	4.7	5.1	0.3
[Sub-total]	31.5	35.2	3.8
Interest and others received (paid)	(1.0)	(1.0)	(0.0)
Income taxes paid	(31.0)	(6.1)	24.9
Net cash provided by (used in) operating activities	(0.5)	28.2	28.7
Capital expenditures (incl. acquisition and others)	(10.2)	(4.3)	5.9
Proceeds from sales of (purchases of) securities	0.1	0.1	0.0
Other	(2.8)	(0.9)	1.9
Net cash used in investing activities	(12.9)	(5.1)	7.8
Net increase (decrease) in short-term borrowings	8.0	(8.0)	(16.0)
Dividends paid	(19.9)	(22.8)	(2.9)
Other-net	(0.3)	(0.3)	(0.0)
Net cash provided by (used in) financing activities	(12.3)	(31.1)	(18.9)
Foreign currency translation adjustments on cash and cash equivalents	(0.6)	(5.7)	(5.0)
Net increase (decrease) in cash and cash equivalents	(26.3)	(13.7)	12.6
Cash and cash equivalents at the beginning of period	131.5	115.1	(16.4)
Cash and cash equivalents at the end of period	105.2	101.4	(3.8)
Free cash flow	(10.7)	23.9	34.6

* "Free cash flow" = "Net cash provided by (used in) operating activities" - "Capital expenditures (incl. acquisition and others)"

Notes

Net cash provided by (used in) operating activities
Declease in income taxes paid because of declining taxable income in the previous year

Net cash used in investing activities
Decrease in expenses of gaining fixed asset and intangible assets

Net cash provided by (used in) financing activities
Repayment of long-term borrowings, increase of amount of dividends paid

4. Financial Results by Business Segment

1) Japan Pharmaceuticals Business

(billions of yen)

	Three months ended Jun 30			Full	
	FY2009	FY2010	YOY %	FY2009	FY2010 est.
Net sales	81.6	86.2	105.6		
Segment profit	34.4	36.8	107.1		
Net sales in Japan					
Pharmaceuticals	74.3	77.1	103.8		
Consumer health care products and other	4.2	4.5	108.2		
Generic drugs (Elmed Eisai Co., Ltd.)	1.7	3.0	175.0		
Diagnostic products (Sanko Junyaku Co., Ltd.)	1.4	1.5	107.1		
Japan ethical drugs (Eisai)					
Anti-Alzheimer's agent Aricept	23.4	25.3	108.0	93.6	109.0
Proton pump inhibitor Pariet	13.4	15.1	112.6	53.8	55.0
Peripheral neuropathy treatment Methycobal	8.3	8.0	95.3	31.3	30.0
Gastritis/gastric ulcer treatment Selbex	4.0	3.1	77.9	14.2	12.0
Osteoporosis treatment Actonel	2.7	2.9	107.2	10.8	12.0
Fully-human monoclonal anti-TNF-alpha antibody Humira	1.2	2.6	215.6	6.6	14.0
Oral anticoagulant Warfarin	2.2	2.4	109.3	8.7	9.5
Muscle relaxant Myonal	2.1	1.8	86.4	7.5	7.0
Non-ionic contrast medium Iomeron	1.9	1.8	91.4	7.0	6.5
Japan consumer health care major groups (Eisai)					
Vitamin B_2 preparation Chocola BB Group	2.3	2.4	104.1	10.5	11.0
Active-type Vitamin B_{12} Nabolin Group	0.6	0.8	142.4	2.3	2.5

2) U.S. Pharmaceuticals Business

	FY2009	FY2010	YOY %

4) Asia Pharmaceuticals Business

6) Sales of Major Products (Eisai)

(1) **Aricept** (Anti-Alzheimer's agent)

		FY2009	FY2010	YOY %	Full FY2009
Japan	Billions JPY	23.4	25.3	108.0	93.6
U.S.	Billions JPY	42.7	50.2	117.6	194.7
	[Millions USD]	[438]	[545]	<124.4>	[2,097]
Europe Total	Billions JPY	7.2	5.8	80.7 <90.7>	27.9
UK	Billions JPY	1.5	1.7	117.0	5.3
	[Millions GBP]	[10]	[13]	<128.8>	[36]
France	Billions JPY	3.5	2.8	79.8	14.3
	[Millions EUR]	[27]	[24]	<90.5>	[109]
Germany	Billions JPY	2.1	1.2	57.2	8.3
	[Millions EUR]	[16]	[10]	<64.8>	[63]

(3) Oncology Related Products

		Three months ended Jun 30			Full
		FY2009	FY2010	YOY %	FY2009
Aloxi (Antiemetic agent)					
U.S.	Billions JPY	9.5	8.8	93.2	38.3
	[Millions USD]	[97]	[96]	<98.6>	[413]
Dacogen (DNA Hypomethylating agent)					
U.S.	Billions JPY	4.2	4.3	103.6	15.4
	[Millions USD]	[43]	[47]	<109.6>	[166]
Fragmin (Injectable anti-clotting agent)					
U.S.	Billions JPY	3.2	4.3	136.3	14.5
	[Millions USD]	[33]	[47]	<144.2>	[156]
Other	Billions JPY	2.9	2.8	97.1	11.6
Total	Billions JPY	19.7	20.3	102.9	79.9

(4) **Humira** (Fully-human monoclonal anti-TNF-alpha antibody)

					Full
		FY2009	FY2010	YOY %	FY2009
Japan	Billions JPY	1.2	2.6	215.6	6.6
Asia	Billions JPY	0.5	0.8	182.7 <180.7>	2.3
Total	Billions JPY	1.7	3.5	206.6	8.9

7) Overseas Sales

(billions of yen)

	FY2009	FY2010	YOY %	Full FY2009
Overseas sales	109.9	114.2	103.9	465.5
Overseas sales (%)	56.5	55.9	-	58.0
<Reference>				
Overseas sales by geographical area	103.9	109.0	104.9	443.4
Overseas sales (%) by geographical area	53.4	53.3	-	55.2

* Net sales to external customers for each segment.
* "Overseas sales by geographical area" is amount of overseas subsidiary companys' sales.

5. Consolidated Balance Sheets

1) Consolidated Balance Sheets <Assets>

(billions of yen)

	Mar 31	%	Jun 30	%	YOY %	Diff.
Cash and cash in banks	69.6		69.4			(0.3)
Notes and accounts receivable-trade	207.2		213.5			6.3
Short-term investments	83.8		75.4			(8.4)
Inventories	67.6		66.1			(1.4)
Deferred tax assets	32.5		39.5			7.0
Other	19.6		19.4			(0.2)
Allowance for doubtful receivables	(0.2)		(0.3)			(0.0)
Total current assets	480.0	43.6	483.0	45.3	100.6	3.0
Buildings and structures-net	86.5		84.4			(2.1)
Other	70.1		68.0			(2.1)
Total property, plant and equipment-net	156.6	14.2	152.4	14.3	97.3	(4.2)
Goodwill	152.8		143.1			(9.6)
Sales rights	109.7		100.3			(9.4)
Core technology	51.0		47.8			(3.2)
Other	12.4		11.7			(0.7)
Total Intangible assets	325.9	29.6	302.9	28.4	92.9	(23.0)
Investment securities	64.8		60.9			(3.9)
Deferred tax assets	63.6		59.0			(4.6)
Other	11.3		7.5			(3.7)

2) Consolidated Balance Sheets <Liabilities and Equity>

(billions of yen)

	2010				YOY	Diff.
	Mar 31	%	Jun 30	%	%	
Notes payable-trade and accounts payable-trade	20.3		23.0			2.7
Short-term borrowings	24.0		16.0			(8.0)
Bonds and debentures(Current portion)	-		40.0			40.0
Accounts payable-other/accrued expenses	127.6		117.8			(9.8)
Income tax payable	6.6		12.9			6.3
Reserve for sales rebates	32.7		33.2			0.5
Other	9.1		8.2			(0.8)
Total current liabilities	220.2	20.0	251.2	23.6	114.1	31.0
Bonds and debentures	120.0		80.0			(40.0)
Long-term borrowings	265.8		263.1			(2.7)
Deferred tax liabilities	23.8		22.1			(1.7)
Liability for retirement benefits	26.4		26.8			0.4
Retirement allowances for directors	2.7		1.1			(1.6)
Other	21.2		23.1			1.9
Total long-term liabilities	459.9	41.7	416.2	39.1	90.5	(43.8)
Total liabilities	680.2	61.7	667.4	62.6	98.1	(12.8)
Common stock	45.0		45.0			-
Capital surplus	56.9		56.9			-
Retained earnings	423.8		419.8			(4.0)
Treasury stock	(39.6)		(39.6)			(0.0)
Total owners' equity	486.1	44.1	482.1	45.2	99.2	(4.0)
Net unrealized gain (loss) on available-for-sale securities	4.9		3.6			(1.3)
Deferred gain (loss) on derivatives under hedge accounting	(0.6)		(1.1)			(0.5)
Foreign currency translation adjustments	(74.4)		(92.3)			(17.9)
Total net unrealized gain (loss) and translation adjustments	(70.2)	(6.4)	(89.8)	(8.4)	127.9	(19.6)
Stock acquisition rights	0.7	0.1	0.8	0.1	104.7	0.0
Minority interests	5.1	0.5	5.0	0.5	99.4	(0.0)
Total equity	421.7	38.3	398.1	37.4	94.4	(23.6)
Total liabilities and equity	1,101.9	100.0	1,065.5	100.0	96.7	(36.4)

Notes

Total liabilities
<Reason for decrease>
Repayment short-term borrowings

Total equity
<Reason for Decrease>

6. Changes in Consolidated Quarterly Results

1) Income Statement Data

(billions of yen)

	FY2010				FY2010
	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter
Net sales	194.7	200.3	209.5	198.7	204.5
Cost of sales	38.3	40.6	42.6	39.2	43.5
R&D expenses	39.4	41.3	36.1	62.3	36.0
SG&A expenses	92.8	93.5	94.8	95.9	92.1
Operating income	24.1	25.0	35.9	1.3	32.8
Ordinary income (decrease)	23.2	22.0	34.9	(0.4)	30.2
Net income (decrease)	16.3	14.6	23.0	(13.6)	18.8
Cash income	30.7	29.1	37.3	29.3	32.6

3) Balance Sheet Data

(billions of yen)

	2009			2010	
	Jun 30	Sep 30	Dec 31	Mar 31	Jun 30
Total assets	1,127.4	1,109.9	1,140.3	1101.9	1,065.5
Liabilities	697.0	686.4	708.3	680.2	667.4
Bonds and debentures	120.9	120.9	120.0	120.0	120.0
Borrowings	307.2	300.1	323.5	289.8	279.1
Equity	430.4	423.5	432.0	421.7	398.1
Shareholders' equity	425.1	418.1	426.4	415.9	392.3
Shareholders' equity ratio to total assets (%)	37.7	37.7	37.4	37.7	36.8
Liabilities ratio Net DER/times)	0.7	0.7	0.6	0.6	0.6

* "Liabilities ratio Net DER)" = ("Interest-bearing debt" ("Borrowings" + "Bonds and debentures") - "Cash and cash in banks" - "Short-term investments" / "Shareholders' equity"

4) Capital Expenditures and Depreciation/Amortization

(billions of yen)

	FY2009				FY2010
	1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter
Capital expenditures	5.8	7.2	6.0	9.7	3.5
Property, plant and equipment	4.8	5.9	4.2	8.0	2.5
Intangible assets	1.0	1.3	1.8	1.7	1.0
Depreciation and amortization	12.1	12.4	12.3	12.1	11.4

* "Depreciation and amortization" includes amortization of "Intangible assets."

5) Sales of Major Products (Eisai)

(1) Aricept

		FY2009				FY2010
		1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter
Japan	Billions JPY	23.4	22.3	26.9	21.0	25.3
U.S.	Billions JPY	42.7	50.1	45.5	56.4	50.2
	[Millions USD]	[438]	[533]	[507]	[619]	[545]
Europe	Billions JPY	7.2	7.1	7.5	6.1	5.8
UK	Billions JPY	1.5	1.3	1.2	1.3	1.7
	[Millions GBP]	[10]	[9]	[8]	[9]	[13]
France	Billions JPY	3.5	3.6	3.8	3.3	2.8
	[Millions EUR]	[27]	[27]	[29]	[27]	[24]
Germany	Billions JPY	2.1	2.2	2.5	1.5	1.2
	[Millions EUR]	[16]	[16]	[19]	[12]	[10]
Asia	Billions JPY	1.6	1.6	1.6	1.8	1.7
China	Billions JPY	0.2	0.4	0.3	0.5	0.3
	[Millions RMB]	[14]	[27]	[26]	[38]	[22]
New markets	Billions JPY	0.0	0.0	0.0	0.0	0.0
Total	Billions JPY	74.8	81.2	81.5	85.3	82.9

(2) Aciphex/Pariet

		FY2009				FY2010
		1st Quarter	2nd Quarter	3rd Quarter	4th Quarter	1st Quarter
Japan	Billions JPY	13.4	12.8	16.9	10.7	15.1
U.S.	Billions JPY	19.8	20.6	20.8	19.7	17.0
	[Millions USD]	[203]	[220]	[231]	[217]	[185]
Europe	Billions JPY	2.1	2.0	2.1	2.0	1.8
UK	Billions JPY	0.6	0.6	0.6	0.5	0.5
	[Millions GBP]	[4]	[4]	[4]	[3]	[4]
Germany	Billions JPY	0.4	0.4	0.4	0.4	0.4
	[Millions EUR]	[3]	[3]	[3]	[3]	[4]
Italy	Billions JPY	0.9	0.9	0.9	0.9	0.6
	[Millions EUR]	[7]	[7]	[7]	[7]	[5]
Asia	Billions JPY	1.4	1.1	1.2	1.1	1.3
China	Billions JPY	0.4	0.2	0.3	0.3	0.4
	[Millions RMB]	[26]	[12]	[20]	[22]	[26]
New markets	Billions JPY	0.0	0.0	0.0	0.1	0.1
Total	Billions JPY	36.7	36.6	41.1	33.6	35.3

(3) Oncology Related Products

. Non-Consolidated Financial Highlights

1) Non-Consolidated Financial Highlights

(1) Income Statement Data

(billions of yen)

	FY2009	FY2010	YOY %	FY2009	FY2010 est.
Net sales	109.2	116.0	106.2	444.7	454.0
Cost of sales	20.9	22.5	107.9	82.3	90.0
R&D expenses	36.8	32.8	89.2	145.3	140.0
SG&A expenses	31.7	30.8	97.3	123.9	137.0
Operating income	19.9	29.9	150.3	93.3	87.0
Ordinary income	19.2	27.9	145.6	88.6	82.0
Net income	14.8	18.4	124.4	57.3	58.5

* "Cost of sales" includes "Provision for (reversal of) sales returns-net."

(2) Cash Flow Data

(billions of yen)

	FY2009	FY2010	Diff.	Full FY2009
Net cash provided by (used in) operating activities	20.7	34.2	13.5	71.5
Net cash used in investing activities	(9.9)	(3.7)	6.2	(31.3)

2) Net Sales by Business Segment

(billions of yen)

	Three months ended Jun 30			Full
	FY2009	FY2010	YOY %	FY2009
Net sales	109.2	116.0	106.2	444.7
Ethical drugs	74.3	77.1	103.8	
Consumer health care products and other	4.2	4.6	108.0	
Industrial property rights and other	17.5	21.5	122.4	
Exports of pharmaceuticals	12.8	12.5	97.5	
Other	0.4	0.4	107.9	

8. Major Events

Date	Description
April 2010	Signed a license agreement with Almirall, S.A. concerning the gastroprokinetic agent cinitapride in China <announced on April 16>
	Postherpetic neuralgia treatment Lyrica Capsules received approval in Japan <announced on April 16>
May	Submitted applications in Japan for twice-daily dosing treatments of proton pump inhibitor Pariet for the treatment of reflux esophagitis <announced on May 6>
	Announced plans to commence a Phase III clinical trial in Japan of the antiepileptic agent rufinamide in patients with Lennox-Gastaut syndrome <announced on May 7>
	Established a pharmaceutical sales subsidiary in Canada <announced on May 11>
	Received approval for an additional indication and additional administration and dosage for anti-arrhythmic agent Tambocor Tablets for the treatment of tachyarrhythmia in pediatric patients in Japan <announced on May 13>
	Issued a notice regarding the issuance of stock acquisition rights for the purpose of granting stock options to employees <announced on May 14>
	Opened a new parenteral oncology drug production facility at Eisai's U.S. plant in North Carolina <announced on May 20>
	Announced plans to present new research on the Company's oncology pipeline and portfolio products at the American Society of Clinical Oncology annual meeting, including new Phase III data on the investigational

9 Major R&D Pipeline

1) R&D Pipeline (Japan, United States, Europe)

R&D Pipeline List

	Product Name	Additional Indication, etc.	Development Stage	Therapeutic Area
New Approval				
1	Tambocor Tachyarrhythmia in pediatric patients	AI, ADA	(Japan) approved	Vascular and Immunological Reaction
1	Pariet Concomitant therapy for eradication of *Helicobacter pylori*	AI	(Japan) approved	Gastrointestinal Disorders
1	Pariet Non-erosive GERD	AI, ADA	(Japan) approved	Gastrointestinal Disorders
1	Aricept Higher dose 23mg tablet	ADA, AF	(US) approved	Neurology
Under Review/Preparing for Submission				
	Aricept Vascular dementia	AI	(US) under review (EU) preparing for submission	Neurology
	E2014 Cervical dystonia		(Japan) under review	Neurology
	KES524 Obesity		(Japan) under review	Other Therapeutic Areas
	Zonegran Orally disintegrating tablet	AF	(EU) under review	Neurology
	E7389 Breast cancer		Japan/US/EU/Switzerland/ Singapore under review	Oncology and Supportive Care
	Humira Crohn's disease	AI	(Japan) under review	Vascular and Immunological Reaction
	Humira Ankylosing spondylitis	AI	(Japan) under review	Vascular and Immunological Reaction
1	Pariet/Aciphex Extended-release 50mg formulation	AF	(US) under review (EU) submission being processed	Gastrointestinal Disorders
1	Pariet Reflux esophagitis	ADA	(Japan) under review	Gastrointestinal Disorders
1	Banzel Oral suspension	AF	(US) under review	Neurology
Clinical				
	E2007 Epilepsy		(US/EU)PIII (Japan)PII	Neurology
1	E2080			

(1) Oncology and Supportive Care

Research Code: **E7389** Generic name: **eribulin mesylate** (Anticancer agent/microtubule dynamics inhibitor)

Description: A synthetic analog of halichondrin B derived from a marine sponge. Believed to exert an antitumor effect by arresting the cell cycle through inhibition of the growth of microtubules. Currently being investigated as a potential treatment for various solid tumors such as breast cancer. A priority review status was granted in the U.S. and Japan.				
	Breast cancer	Switzerland: under review(July 2009) Singapore: under review(July 2009) US: submitted(March 2010), accepted(May 2010) EU: submitted(March 2010), accepted(May 2010) Japan: under review(March 2010)		Inj.
	Non small cell lung cancer	US: PII		Inj.
	Prostate cancer	US: PII EU: PII		Inj.
	Sarcoma	EU: PII		Inj.

Research Code: **E7820** (Anticancer agent/angiogenesis inhibitor that suppresses alpha 2 integrin expression)

Description: An angiogenesis inhibitor that suppresses the expression of alpha 2 integrin, an adhesion molecule of vascular endothelial cells.				
	Colorectal cancer	US: PII		Oral

Research Code: **E7080** (Anticancer agent/VEGF receptor tyrosine kinase inhibitor)

Description: An anti-angiogenic agent that inhibits tyrosine kinase of a VEGF receptor, VEGFR2. Currently being investigated as a potential treatment for various solid tumors.				
	Thyroid cancer	US: PII EU: PII		Oral
	Endometrial cancer	US: PII		Oral
[1]	Melanoma	US: PII		Oral

Research Code: **MORAb-003** Generic name: **farletuzumab** (Anticancer agent/monoclonal antibody)

Description: A humanized IgG1 MAb that targets folate receptor alpha (FRA). Expected to exhibit an antitumor effect against carcinomas that over express FRA. A Phase III study was initiated in Japan for ovarian cancer. The study is now ongoing in the European Union, the United States and Japan, and is being conducted a global development program.				
[1]	Ovarian cancer	Global Development Program: PIII	Submission Target FY2012	Inj.

Research Code: **MORAb-009** Generic name: **amatuximab** (Anticancer agent/monoclonal antibody)

Description: A chimeric IgG1 MAb that blocks the function of mesothelin. Expected to exhibit an anti-tumor effect against carcinomas that express methothelin.				
	Mesothelioma	US: PII EU: PII		Inj.

Product Name: **Dacogen** Research Code: **E7373** Generic name: **decitabine** (DNA methylation inhibitor)

Description: Induces cell differentiation through inhibition of DNA methylation. Currently approved for the treatment of myelodysplastic syndromes (MDS) in the United States.				
	Additional Indications: Acute myelogenous leukemia (AML)	US: PIII	Submission Target FY2010	Inj.

[1] development progress from April 2010 onwards
ċ submission target changed from the previous announcement

Research Code: **E7850** Generic Name: **irofulven** (Anticancer agent/DNA synthesis inhibitor)

Description: Believed to exhibit an anticancer effect by inhibiting DNA synthesis.			
Prostate cancer, etc	US: PII		Inj.

Research Code: **E5501/AKR-501** (Treatment for thrombocytopenia/thrombopoietin receptor agonist)

Description: An oral thrombopoietin receptor agonist that increases platelet production. Expected to exhibit effects against conditions that show thrombopenia.			
Idiopathic thrombocytopenic purpura(ITP)	US: PII	Submission Target FY2012	Oral
Thrombocytopenia associated with liver disease(TLD)	US: PII		Oral

Research Code: **E7101** Generic name: **amolimogene bepiplasmid** (Treatment for cervical dysplasia/therapeutic DNA vaccine)

Description: A therapeutic DNA vaccine against human papilloma virus (HPV), which is believed to cause diseases such as cervical dysplasia.

[1] development progress from April 2010 onwards
ċ submission target changed from the previous announcement

Research Code: **E2007** Generic name: **perampanel** (AMPA receptor antagonist)

Description: A selective AMPA-subtype glutamate receptor antagonist for the treatment of a variety of neurological disorders.			
Epilepsy	US: PIII EU: PIII Japan: PII	Submission Target FY2011	Oral
Neuropathic pain	US: PII EU: PII		Oral
Multiple sclerosis	EU: PII		Oral
Migraine prophylaxis	US: PII		Oral

Research Code: **AS-3201** Generic name: **ranirestat** (Treatment for diabetic complications/aldose reductase inhibitor)

Description: An aldose reductase inhibitor that is believed to reduce intracellular accumulation of sorbitol. Currently being investigated as a potential treatment for diabetic neuropathy, one of the most common diabetic complications.			
Diabetic neuropathy	US: PII/III EU: PII/III		Oral

Product Name: **Zonegran** Research Code: **E2090** Generic name: **zonisamide** (Anti-epileptic agent)

Description: Believed to exhibit a wide anti-epileptic spectrum and is well-tolerated. Currently indicated as an adjunctive therapy in the treatment of patients with partial seizures.			
Additional Formulations: Orally disintegrating tablet	EU: under review March 2009 , Accepted March 2009		Oral
Additional Indications: Pediatric epilepsy	EU: PIII	Submission Target FY2011	Oral
ċ **Additional Indications:** Monotherapy for epilepsy	EU: PIII	Submission Target FY2011	Oral

Research Code: **E0302** Generic name: **mecobalamin**

[1] development progress from April 2010 onwards
ċ submission target changed from the previous announcement

[1] development progress from April 2010 onwards
ċ submission target changed from the previous announcement

(4) Gastrointestinal Disorders

Product Name: **Pariet/Aciphex** Research Code: **E3810** Generic name: **rabeprazole** (Proton pump inhibitor)

Description: A proton pump inhibitor approved for the treatment of gastric and duodenal ulcers, reflux esophagitis and eradication of *Helicobacter pylori* infections, etc.			
[1]	**Additional Indications, Additional Dosage & Administration:** Non-erosive gastroesophageal reflux disease (GERD)	Japan: approved(June 2010)	Oral
[1]	**Additional Indications:** concomitant therapy for eradication of *Helicobacter pylori* in gastric MALT lymphoma, the stomach after endoscopic resection of early stage gastric cancer, and idiopathic thrombocytopenic purpura	Japan: approved(June 2010)	Oral
[1]	**Additional Formulation:** Extended-release 50mg formulation	US: submitted(March 2010), accepted(June 2010) EU: submission being processed	Oral
[1]	**Additional Dosage & Administration:** Reflux esophagitis	Japan: under review(April 2010)	Oral
	Additional Indications: Functional dyspepsia	Japan: PII	Oral

(5) Other Therapeutic Areas

Research Code: **KES524** Generic name: **sibutramine** (Anti-obesity agent/central acting serotonin & noradrenaline reuptake

[1] development progress from April 2010 onwards
ċ submission target changed from the previous announcement